Evidence have proven the efficacy and safety of tocilizumab, a recombinant humanized IgG1 monoclonal antibody that targeted interleukin-6 (IL-6) receptors, in the treatment of RA. The gene discussed is IL6; the disease is rheumatoid arthritis.